Khaled Aida, Kharfi Monia, Zaouek Anissa, Rameh Soumaya, Zermani Rachida, Fazaa Becima, Kamoun Mohamed Ridha
Department of Dermatology, Charles Nicolle Hospital, Tunis, Tunisia.
Pediatr Dermatol. 2012 Jul-Aug;29(4):525-7. doi: 10.1111/j.1525-1470.2011.01548.x. Epub 2011 Aug 19.
We report a new case of postvaccination morphea profunda (MP) in a child and discuss its different clinical presentations, prognosis, and therapy and its relationship with "solitary morphea profunda." A 2-year-old healthy girl presented with an induration of the anterior aspect of the left thigh of 9 months duration. The lesion had appeared 3 months after a third dose of diphtheria-tetanus-pertussis vaccine. Cutaneous examination showed an induration of 7 × 7 cm with an "orange peel" texture after pinching the skin. Histologic examination confirmed the diagnosis of MP. Systemic steroids (1 mg/kg/day) led to the stabilization of the lesion. After 4 months of treatment, we began the concomitant use of oral methotrexate (10 mg/wk) for 2 months. Methotrexate was then continued alone for 10 months, leading to a significant regression of the induration with no relapse.
我们报告了一例儿童接种疫苗后发生的深部硬斑病（MP）新病例，并讨论了其不同的临床表现、预后、治疗及其与“孤立性深部硬斑病”的关系。一名2岁健康女孩，左大腿前侧出现硬结9个月。该病变在第三次接种白喉-破伤风-百日咳疫苗3个月后出现。皮肤检查显示，捏起皮肤后有一个7×7厘米的硬结，质地如“橘皮”。组织学检查确诊为MP。全身使用类固醇（1毫克/千克/天）使病变稳定。治疗4个月后，我们开始联合口服甲氨蝶呤（10毫克/周）2个月。然后单独继续使用甲氨蝶呤10个月，硬结明显消退且无复发。
